Novartis stock drops 10% after trial failures
Novartis stock dropped 10% after their drug "Dile Diziran" failed in the final trial for treating muscle wasting disorder, resulting in the company's worst trading day. This decline follows the failure of their drug "Belacarsin" to reduce the risk of cardiovascular diseases, and the suspension of "RAB Cell" therapy trials after the death of three patients. The results of these trials confirm that the drugs did not achieve the desired goals in treating chronic diseases, raising investors' concerns about the company's potential misrepresentations in its drug development efforts.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)